Accutane Once-Daily Version Should Have Three-Year Phase-In - FDA Cmte.
Executive Summary
Roche should take three years to replace the current formulation of Accutane (isotretinoin) with a once-daily version, FDA Dermatologic & Ophthalmic Drugs Advisory Committee voting consultant Lloyd King, MD/PhD, said during the panel's Sept. 19 meeting.
You may also be interested in...
Accutane Psychiatric Safety Trial Planned: Roche Prepares For Hearings
Roche and FDA are in discussions about the design for a prospective study to resolve questions about a potential link between the acne drug Accutane (isotretinoin) and psychiatric side effects.
House Accutane Safety Hearing Will Include Testimony From FDA's Woodcock
FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, is scheduled to testify on patient safety issues related to Roche's acne drug Accutane during a Dec. 5 hearing convened by the House Government Reform Committee.
House Accutane Safety Hearing Will Include Testimony From FDA's Woodcock
FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, is scheduled to testify on patient safety issues related to Roche's acne drug Accutane during a Dec. 5 hearing convened by the House Government Reform Committee.